Cymabay Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

CymaBay Therapeutics

01/11/2021 22:59

* Cymabay Therapeutics Inc  CBAY.OQ   CBAY.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 3 (estimated). 
* The Newark California, California-based company is expected to
report revenue of $6.25 million, according to the mean estimate
from 8 analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Cymabay Therapeutics
Inc is for a loss of 26 cents per share. For the same quarter
last year, the company reported a loss of 17 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $12​, about 65.3% above​ its last closing
price of $4.17. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -0.27       -0.27      -0.34     Missed  -27
 Mar. 312021   -0.25       -0.24      -0.25     Missed  -2.4
 Dec. 312020               -0.20      -0.23     Missed  -14.9​
 Sep. 302020   -0.17       -0.17      -0.17     Met     -2.4
 ​​Jun.        -0.23       -0.24      -0.16     Beat    33.1
 302020                                                 
 Mar. 312020   -0.30       -0.30      -0.19     Beat    36.5​
 Dec. 312019   -0.37       -0.39      -0.35     Beat    10
 Sep. 302019   -0.38       -0.37      -0.38     Missed  -3.1
 This summary was machine generated November 1 at 22:59 GMT.  All
figures in US dollars unless otherwise stated